Research programme: P80DOX-NP - Advectus

Drug Profile

Research programme: P80DOX-NP - Advectus

Alternative Names: Doxorubicin nanoparticle formulation; Doxorubicin nanoparticles - Advectus; P80 DOX-NP

Latest Information Update: 01 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advectus Life Sciences; University of North Carolina at Chapel Hill
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Sep 2006 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 01 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 04 Jul 2002 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top